| |
| |
|
| Insider
Information: |
Beshar Luke M |
| Relationship: |
Director |
| City: |
East Rutherford |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
198,000 |
|
|
Indirect Shares
|
1,081 |
|
|
| Direct
Value |
$556,380 |
|
|
|
Indirect Value
|
$64,795 |
|
|
| Total
Shares |
199,081 |
|
|
| Total
Value |
$621,175 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -4.2%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cambrex Corp |
CBM |
Executive Vice President |
2007-10-10 |
0 |
2005-12-31 |
1,081 |
Premium* |
|
|
NPS Pharmaceuticals Inc |
NPSP |
EVP & CFO |
2015-02-21 |
0 |
2011-01-31 |
0 |
Premium* |
|
|
Regenxbio Inc. |
RGNX |
|
2018-11-29 |
0 |
2018-11-19 |
0 |
Premium* |
|
|
Protara Therapeutics, Inc |
TARA |
Director |
2022-06-30 |
198,000 |
2020-01-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
77 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-19 |
4 |
OE |
$12.74 |
$288,138 |
D/D |
12,116 |
12,116 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-19 |
4 |
AS |
$60.26 |
$733,602 |
D/D |
(12,116) |
0 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-20 |
4 |
AS |
$60.38 |
$1,278,607 |
D/D |
(21,176) |
0 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-20 |
4 |
OE |
$3.76 |
$191,963 |
D/D |
21,176 |
21,176 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-26 |
4 |
OE |
$49.45 |
$85,103 |
D/D |
1,721 |
1,721 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-26 |
4 |
AS |
$65.00 |
$111,865 |
D/D |
(1,721) |
0 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-27 |
4 |
AS |
$65.03 |
$1,221,654 |
D/D |
(18,786) |
0 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-27 |
4 |
OE |
$3.76 |
$346,908 |
D/D |
18,786 |
18,786 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-29 |
4 |
AS |
$65.00 |
$830,960 |
D/D |
(12,784) |
0 |
0 |
- |
|
| RGNX |
Regenxbio Inc. |
|
– • – |
2018-11-29 |
4 |
OE |
$3.76 |
$48,068 |
D/D |
12,784 |
12,784 |
0 |
- |
|
| TARA |
Protara Therapeutics, Inc |
Director |
– • – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
168,000 |
168,000 |
0 |
- |
|
| TARA |
Protara Therapeutics, Inc |
Director |
– • – |
2022-03-10 |
4 |
B |
$4.46 |
$44,555 |
D/D |
10,000 |
178,000 |
2.39 |
% |
|
| TARA |
Protara Therapeutics, Inc |
Director |
– • – |
2022-03-14 |
4 |
B |
$4.25 |
$42,500 |
D/D |
10,000 |
188,000 |
2.39 |
% |
|
| TARA |
Protara Therapeutics, Inc |
Director |
– • – |
2022-06-30 |
4 |
B |
$3.10 |
$31,000 |
D/D |
10,000 |
198,000 |
2.39 |
% |
|
| CBM |
Cambrex Corp |
EVP & CFO |
• – – |
2004-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
296 |
589 |
|
- |
|
| CBM |
Cambrex Corp |
EVP & CFO |
• – – |
2005-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
7,551 |
11,072 |
|
- |
|
| CBM |
Cambrex Corp |
EVP & CFO |
• – – |
2005-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
492 |
1,081 |
0 |
- |
|
| CBM |
Cambrex Corp |
EVP & CFO |
• – – |
2006-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,437 |
19,509 |
0 |
- |
|
| CBM |
Cambrex Corp |
EVP & CFO |
• – – |
2006-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
22,909 |
|
- |
|
| CBM |
Cambrex Corp |
EVP & CFO |
• – – |
2007-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,929 |
32,838 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
EVP & CFO |
• – – |
2012-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
26,900 |
26,900 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
EVP & CFO |
• – – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,966 |
49,539 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
EVP & CFO |
• – – |
2013-02-07 |
4 |
D |
$8.61 |
$30,040 |
D/D |
(3,489) |
46,050 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
EVP & CFO |
• – – |
2013-02-19 |
4 |
D |
$8.01 |
$55,029 |
D/D |
(6,870) |
59,180 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
EVP & CFO |
• – – |
2013-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
66,050 |
0 |
- |
|
77 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
